Fig. 5.

Anti-CD8 mAb treatment promotes an increase in the number of CD4⁺ KJ1-26⁺ cells in tolerant mice. BALB/c mice were injected with 2.5 × 10⁶ CD4⁺ KJ1-26⁺ cells isolated from BALB/c DO11.10 mice and, on the same day, treated with either OVA alone or, OVA and anti-CD4 mAb plus isotype control or, with OVA and anti-CD4/anti-CD8 mAb cocktail. On day 42 after OVA and mAb treatment mice from each group were either boosted with OVA or left without a boost. Splenocytes were isolated from mice in each group at 3 (panel a) and 6 (panel b) days post-boost and the total number of CD4⁺ KJ1-26⁺ cells was determined for each mouse by FACS. Additional mice from the groups of mice that were treated with either OVA and the anti-CD4/anti-CD4 mAb plus isotype control and boosted on day 42 were boosted again on day 72 with either OVA or β-gal. After a further 3 days splenocytes were isolated from each group and the number of CD4⁺ KJ1-26⁺ cells determined. Data shown are mean±SEM for each group and are representative of 2 experiments. * indicates statistical significance to 0.01–0.05. ** indicates statistical significance to 0.001–0.009. The student t test was used to determined statistical significance. n = 3 per group.